Table 5.
Baseline characteristics and outcome data in relapsing and nonrelapsing participants from NICE and GEMRITUX cohorts treated with rituximab
| Participants Characteristics | Relapse (n=8) | No Relapse (n=33) |
|---|---|---|
| Baseline characteristics | ||
| Age | 60 [51; 70] | 57 [46; 68] |
| Sex ratio (F/M) | 2/6 | 9/24 |
| Proteinuria (g/g of creatinine) | 6.3 [5.2; 12.7] | 7.0 [4.7; 9.3] |
| Serum albumin (g/dl) | 2.0 [1.1; 2.2] | 2.3 [1.8; 2.7] |
| Serum creatinine (mg/dl) | 1.1 [0.8; 1.4] | 1.1 [0.9; 1.4] |
| BP (mm Hg) | ||
| Systolic | 120 [ 108; 127] | 120 [114; 140] |
| Diastolic | 63 [60; 80] | 80 [68; 81] |
| Anti-PLA2R1 titer (RU/ml) at first infusion | 113.8 [35.3; 249.4] | 100.5 [38.3; 213.7] |
| Spreadinga | ||
| No | 0 (0) | 17 (52) |
| Yes | 8 (100) | 16 (48) |
| Characteristics at month 3 | ||
| Serum rituximab (μg/ml) | 3.1 [0.0; 6.6] | 0.0 [0.0; 7.5] |
| Anti-PLA2R1 titer (RU/ml) | 7.5 [0.0; 49.1] | 0.0 [0.0; 11.0] |
| CD19 count | 0.0 [0.0; 13.7] | 1.0 [0.0; 17.25]b |
| Characteristics at month 6 | ||
| Anti-PLA2R1 titer (RU/ml) | 9.5 [0.0; 37.0] | 0 [0.0; 3.0] |
| CD19 count | 19.0 [11.7; 64.2] | 34.0 [5.9; 83.5]c |
| Rate of PLA2R1 antibody depletiona | 4/8 (50) | 5/33 (9) |
Quantitative values are medians [interquartile ranges]; qualitative values are numbers. F/M, female/male; PLA2R1, M-type phospholipase A2 receptor.
a
P<0.05.
b
Two points are missing.
c
Three points are missing.